Bifission pregnane type steroid derivative as well as preparation method and application thereof

By preparing and applying double-fissing pregnancies C21 steroid derivatives, the shortcomings in the prevention and treatment of tobacco mosaic viruses in the prior art have been solved, efficient antiviral activity and safe and environmentally friendly pesticide development have been achieved, and the tobacco flowering has been significantly improved. The prevention and control effect of leaf virus.

CN118994297APending Publication Date: 2024-11-22GUIZHOU MEDICAL UNIV
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202411101163.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-12
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The prior art lacks effective natural products for the prevention and control of tobacco mosaic viruses. Traditional chemical control has problems with drug resistance and pesticide residues, and there are a lack of disease-resistant varieties. It is necessary to develop new pesticides to cope with the increase in plant viral diseases.

Method used

Provided double-fission pregnanate type C21 steroid derivatives and preparation methods and prepare high-active compounds 5e, 5g, 5h, 5j, 5k, 5l and 10a by introducing different substituents, for inhibiting the infection of tobacco mosaic virus, by Inhibit viral subgenomic RNA expression and reduce NtHsp70-1 and NtHsp70-061 expression, significantly improving antiviral activity.

Benefits of technology

Compounds 5e, 5g, 5j, 5l showed stronger anti-TMV passivation, protective and therapeutic activity than the positive control ningnanmycin, and had higher EC50 values ​​than the positive control, and significantly reduced tobacco flower leaves when used in combination with other antiviral preparations. Virus expression and infection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118994297A_ABST
    Figure CN118994297A_ABST
Patent Text Reader

Abstract

The invention discloses a double-split pregnane type steroid derivative as well as a preparation method and application thereof. According to the invention, bisplit pregnane type C21 steroid compounds 1 and 2 separated from cynanchum paniculatum as a metaplexaceae cynanchum plant are respectively hydrolyzed to remove glycosyl to obtain C21 steroid aglycones 3 and 4, different substituents are introduced to the site 3 of the compound 3 and the site 2 and the site 3 of the compound 4 to prepare a plurality of derivatives, and preferably, the high-activity plant tobacco mosaic virus resistant derivatives are obtained. The derivatives 5e, 5g, 5h, 5j, 5k, 5l and 10a provided by the invention all show relatively strong TMV passivation resistance activity, and the TMV passivation resistance activity is higher than that of positive control ningnanmycin. Meanwhile, the EC50 values of the compounds are higher than those of positive control ningnanmycin. The compounds 3, 4, 5 g, 5j and 5l show passivation, protection and treatment effects superior to those of positive control ningnanmycin and compounds 3 and 4, and are high-activity plant virus-resistant candidates preferably selected by the invention.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of natural products, in particular to a bisected pregnane-type steroid derivative and a preparation method and application thereof. Background Art

[0002] Tobacco mosaic virus (TMV) is one of the earliest and most well-known plant viruses, capable of infecting more than 800 plant species, including tobacco, tomatoes, peppers, potatoes and cucumbers. Given the prevalence of plant viruses and the lack of direct treatment measures, the increasing incidence of viral diseases has put agricultural systems at greater risk. At present, the prevention and control of viral diseases in production is mainly through insect control and disease prevention, but its transmission vectors are prone to drug resistance, and crops are prone to excessive pesticide residues. In addition, there is a lack of disease-resistant varieties, and there is still a lack of effective prevention and control measures in production. In addition, compared with traditional chemical control, plant-based antiviral agents have the advantages of safety and environmental protection, low toxicity or non-toxicity, easy degradation, and not easy to develop resistance. Therefore, in recent years, lead discovery and optimization based on natural products have become a key method for the development of new pesticides. For example, the Chinese patent with publication number CN111418595A discloses C in Xu Changqing. 21 Application of steroidal compounds 1-8 in the preparation of anti-TSWV active products.

[0003] In the early stage of this application, research on the discovery of new antiviral drug candidates based on natural products was also carried out. In the process of discovering antiviral drug candidates, a new type of 13,14:14,15-bilobenzane-type C 21 Steroids showed high antiviral activity against tobacco mosaic virus (TMV). Further studies on the antiviral mechanism showed that pregnane-type C 21 Steroids inhibit TMV by inhibiting the expression of viral subgenomic RNA but do not affect the expression of viral genomic RNA. 21 There is no documented report on the effects of the 3-position substituent of steroidal glaucogenin C (3) and the 2,3-position substituent of glaucogenin A (4) on their biological activities. The 3-position of glaucogenin C and the 2,3-position of glaucogenin A are both hydroxyl groups, and the introduction of substituents therein may have a significant effect on their biological activities. Summary of the invention

[0004] In view of the shortcomings of the prior art, the present invention provides multiple bisected pregnane type C 21 Steroidal derivatives and their application in combating tobacco mosaic virus disease.

[0005] In order to solve the above technical problems, the technical solution of the present invention is as follows:

[0006] In a first aspect, the present invention provides a bisected pregnane type C 21A steroidal derivative, wherein the structure of the derivative is shown in general formula I or general formula II:

[0007]

[0008] In the general formulae I and II, R1, R2, and R3 are selected from the group consisting of hydrogen, alkanes, alkenes, dienes, alkynes, benzene, biphenyl, condensed aromatic rings, aromatic heterocycles, various electron-donating and electron-withdrawing aromatic rings, carboxyl groups, ester groups, acyl groups, and cyano groups.

[0009] Preferably, the derivative is compound 5e, 5g, 5h, 5j, 5k, 5l or 10a;

[0010] The structural formula of the compound 5e, 5g, 5h, 5j, 5k, 5l or 10a is as follows:

[0011]

[0012] As a further preference, the derivative is compound 5g, 5j or 5l; in the in vivo anti-tobacco mosaic virus activity test, the derivatives 5g, 5j and 5l all showed stronger passivation, protection and therapeutic activities than the positive control ningnanmycin and the lead compound glaucogenin C.

[0013] In a second aspect of the present invention, there is provided the bisected pregnane type C 21 The preparation method of steroidal derivatives, the synthesis method of compound 5e, 5g, 5h, 5j, 5k or 5l is as follows:

[0014] Step (1) Biscission Pregnane Type C 21 The steroid compound 1 is dissolved in tetrahydrofuran, and HCl solution is added thereto, and the mixture is heated and stirred for reaction; after the reaction is completed, the mixture is cooled to room temperature, an alkali solution is added to the reaction system for neutralization, and then extracted with dichloromethane; after concentration, the crude product is purified by flash chromatography to obtain compound 3;

[0015] The structural formulas of the compounds 1 and 3 are as follows:

[0016]

[0017] Step (2) The 3-hydroxyl group in compound 3 undergoes nucleophilic substitution reaction with the corresponding acyl chloride compound to obtain compound 5e, 5g, 5h, 5j, 5k or 5l.

[0018] Preferably, the bisected pregnane type C 21The molar volume ratio of the steroid compound 1, tetrahydrofuran and HCl solution is 90-100 mol:8-12 L:8-12 L; the concentration of the HCl solution is 0.8-1.5 N (mol / L); the reaction temperature of step (1) is 60-70° C., and the reaction time is 30-90 min.

[0019] Preferably, the preparation process of the compound 5e is as follows: weigh compound 3 and dissolve it in dichloromethane, and under nitrogen protection, add acetic anhydride, pyridine and 4-dimethylaminopyridine to the solution at 0-2°C and stir to react; warm the mixture to room temperature and stir for 2-12 hours; then add saturated NaHCO3 solution to the solution, and extract the resulting mixture three times with ethyl acetate; then wash the organic layer with saturated brine, dry with Na2SO4, and concentrate under vacuum, and purify the crude product by flash chromatography to obtain pure compound 5e;

[0020] The molar ratio of the compound 3, acetic anhydride and 4-dimethylaminopyridine is 1:1-2:0.08-0.15; the molar volume ratio of the compound 3 and dichloromethane is 0.8-1.2 mol:30-60 mL; the molar volume ratio of the acetic anhydride and pyridine is 0.1-0.2 mol:0.8-1.5 L.

[0021] Preferably, the preparation process of the compounds 5g, 5h, 5j, 5k and 5l is as follows: take 5 reaction bottles, weigh compound 3 in each reaction bottle and mix it with pyridine and dichloromethane, add corresponding amounts of acyl chloride compounds p-chlorobenzoyl chloride, cyclopropanecarbonyl chloride, 2-furancarbonyl chloride, 2-thiophenecarbonyl chloride and 4-trifluoromethylthiobenzoyl chloride to each reaction bottle under nitrogen protection at room temperature for reaction; then add water for suspension, and extract the mixture with ethyl acetate; wash the combined extract with saturated brine and dry it with anhydrous Na2SO4; filter the organic solution and concentrate it under vacuum, purify the combined extract by column chromatography on a silica gel column to obtain the corresponding target compounds 5g, 5h, 5j, 5k and 5l, respectively;

[0022] The molar volume ratio of the compound 3, pyridine and dichloromethane is 0.08-0.15 mol: 8-15 L: 10-30 L; the molar ratio of the compound 3 and the acyl chloride compound is 1: 1-2; and the reaction time is 20-30 h.

[0023] Preferably, the synthesis method of compound 10a comprises the following steps:

[0024] Step S1: Biscispregnane type C 21The steroid compound 2 is dissolved in tetrahydrofuran, and HCl solution is added thereto, and the obtained mixture is heated and stirred for reaction; the mixture is then cooled to room temperature, and an alkali solution is added for neutralization; the obtained mixture is extracted with dichloromethane, and the extract is concentrated under vacuum; the crude product is purified by flash chromatography to obtain compound 4;

[0025] The structural formulas of the compounds 2 and 4 are as follows:

[0026]

[0027] As a further preferred embodiment, the bisected pregnane type C in step S1 21 The molar volume ratio of steroid compound 2, tetrahydrofuran and HCl solution is 90-100 mol:8-12 L:8-12 L; the concentration of the HCl solution is 0.8-1.5 N (mol / L); the reaction temperature of step S1 is 60-70° C., and the reaction time is 30-90 min;

[0028] Step S2: Weigh compound 4, pyridine and dichloromethane, add a corresponding amount of 2-furoyl chloride under nitrogen protection at room temperature for 20-30 hours; then suspend in water, and extract the reaction mixture with ethyl acetate; wash the combined organic layer with saturated brine, dry with Na2SO4, and concentrate under vacuum; purify the extract by flash chromatography to obtain pure compound 10a;

[0029] As further preferred, in step S2, the molar volume ratio of the compound 4, pyridine and dichloromethane is 0.08-0.15 mol:8-15 L:10-30 L; the molar ratio of the compound 3 and 2-furoyl chloride is 1:2-4, and the reaction time is 20-30 h.

[0030] In a third aspect of the present invention, there is provided the bisected pregnane type C 21 Application of steroidal derivatives in inhibiting, preventing, controlling or treating tobacco mosaic virus.

[0031] As a further description of the above scheme: Compound 5g, 5j, 5l or a pharmaceutically acceptable salt, ester or stereoisomer thereof can be used alone as an anti-tobacco mosaic virus preparation.

[0032] As a further description of the above scheme: the derivative can be used in combination with other carriers, other antiviral preparations or pesticides, and the percentage content of the derivative is 0.1% to 99.9%.

[0033] The present invention is a bifid pregnane type C isolated from Cynanchum chinense of the genus Cynanchum of the family Apocynaceae. 21Steroidal glaucogenin C3-O-β-d-cymaropyranoside (1) and glaucogenin A 3-O-β-d-cymaropyranoside (2) were hydrolyzed to remove the sugar moiety to obtain C 21 Steroidal aglycones glaucogenin C (3) and glaucogenin A (4), different substituents are introduced at the 3-position of glaucogenin C (3) and the 2- and 3-positions of glaucogenin A (4) to prepare derivatives, the general structural formulas being I and II, respectively, and preferably obtaining derivatives with high activity against tobacco mosaic virus. The present invention provides a novel structure of anti-tobacco mosaic virus derivatives, and the anti-tobacco mosaic virus activity thereof is related to reducing the expression of tobacco mosaic virus coat protein (TMV-CP) and the replication of TMV-CP gene. At the same time, the expression of NtHsp70-1 and NtHsp70-061 is downregulated, further indicating that the bifidopamine type C 21 The inhibition of tobacco mosaic virus infection by steroidal derivatives was also associated with a reduction in the levels of NtHsp70-1 and NtHsp70-061.

[0034] Compared with the prior art, the present invention has the following beneficial effects: the compounds 5e, 5g, 5h, 5j, 5k, 5l and 10a provided by the present invention all exhibit strong anti-TMV passivation activity, which is higher than that of the positive control Ningnanmycin. 50 The values ​​were higher than those of the positive control Ningnanmycin. Compounds 5g, 5j and 5l showed better purification, protection and therapeutic effects than the positive control Ningnanmycin and lead compounds 3 and 4, and were selected as highly active anti-plant virus candidates by the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0035] Figure 1 The results of the in vivo half-leaf spot test of the anti-plant virus candidates 5g, 5j and 5l of Nicotiana tabacum;

[0036] Figure 2 Analysis of TMV-CP protein and gene expression. A. Expression of TMV-CP was detected by Western blotting on day 3 after virus-inoculated leaves were treated with compounds 5e, 5g, 5h, 5j, 5k, 5l, and 10a. B. RT-PCR analysis of TMV-CP gene expression in systemically infected leaves;

[0037] Figure 3 The expression of Hsp70 was detected by Western blotting on the 3rd day after the virus-inoculated leaves were treated with compounds 5e, 5g, 5h, 5j, 5k, 5l, and 10a;

[0038] Figure 4 The expression of NtHSP70-1, NtHSP70-061, and NtHSP70-261 genes in systemically infected leaves was evaluated by RT-qPCR analysis 3 days after the virus-inoculated leaves were treated with compounds 5e, 5g, 5h, 5j, 5k, 5l, and 10a. DETAILED DESCRIPTION

[0039] The technical solution of the present invention is further described in detail below in conjunction with the accompanying drawings and specific embodiments, but the present invention is not limited to the following technical solution.

[0040] The 3-substituted glaucogenin C derivatives 5e, 5g, 5h, 5j, 5k, 5l of the general formula I of the present invention can be prepared by the method described in the following reaction formula: the bisected pregnane C isolated from Cynanchum chinense of the genus Cynanchum of the family Apocynaceae 21 The steroidal glaucogenin C 3-O-β-d-cymaropyranoside (1) was hydrolyzed to remove the sugar group to obtain glaucogenin C (3), and then the 3-position was substituted to obtain compounds 5e, 5g, 5h, 5j, 5k, and 5l.

[0041]

[0042] The 2,3-substituted glaucogenin A derivative 10a of the general formula II of the present invention can be prepared according to the method described in the following reaction formula: the bisected pregnane type C isolated from Cynanchum chinense of the genus Cynanchum of the family Apocynaceae 21 The steroidal glaucogenin A3-O-β-d-cymaropyranoside (2) was hydrolyzed to remove the sugar group to obtain glaucogenin A (4), and then 2,3-position substitution was performed to obtain compound 10a.

[0043]

[0044] The detailed synthesis process of each compound can be found in the following examples.

[0045] Example 1 Synthesis of Lead Compound 3

[0046]

[0047] Bischiate pregnane C isolated from Cynanchum chinense 21Steroidal glaucogenin C3-O-β-d-cymaropyranoside (1), compound 1 (95.2 mmol) was dissolved in 10 mL of tetrahydrofuran, 10 mL of 1N HCl was added thereto, and the resulting mixture was stirred at 65°C for 1 hour. The mixture was then cooled to room temperature, and 30 mL of saturated NaHCO3 was added; the resulting mixture was extracted with dichloromethane (DCM), and the extract was concentrated under vacuum. The crude product was purified by flash chromatography to obtain compound 3 (glaucogenin C). White solid, yield 98.3%; melting point 205.3-206.2°C. 1 HNMR (600MHz, CDCl3) δ6.25(s,1H),5.39(d,J=5.2Hz,1H),5.31-5.29(m,1H),4.16(dd,J=8.6,7.0Hz,1H),3.85(t ,J=8.8Hz,1H),3.56-3.50(m,1H),3.44(d,J=7.8Hz,1H),2.60-2.54(m,1H),2.44(q,J=10.6Hz,2H),2.33-2.31(m, 1H),2.19-2.15(m,1H),2.10-2.08(m,1H),2.07-2.04(m,1H),1.96(dt,J=13.3,3.3Hz,1H),1.53(s,3H),1.52-1. 48(m,1H),1.35-1.32(m,1H),1.27-1.25(m,2H),1.20(t,J=9.8Hz,1H),1.07(td,J=13.6,3.6Hz,1H),0.93(s,3H). 13 C NMR (150MHz, CDCl3) δ175.7,143.5,140.4,120.3,118.3,114.1,75.2,71.7, 67.7,55.8,52.9,42.1,40.6,38.5,36.5,31.5,29.8,28.1,24.7,23.7,18.2. HRMS(ESI)calcd for C 21 H 28 O5Na[M+Na] + ,383.1834;found,383.1823; (c 0.86, MeOH).

[0048] Example 2 Synthesis of Lead Compound 4

[0049]

[0050] Bischiate pregnane C isolated from Cynanchum chinense 21 Steroidal glaucogenin A3-O-β-d-cymaropyranoside (2), compound 2 (95.2 mmol) was dissolved in 10 mL of tetrahydrofuran, 10 mL of 1N HCl was added thereto, and the resulting mixture was stirred at 65°C for 1 hour. The mixture was then cooled to room temperature, and 30 mL of saturated NaHCO3 was added; the resulting mixture was extracted with dichloromethane (DCM), and the extract was concentrated under vacuum. The crude product was purified by flash chromatography to obtain compound 4 (glaucogenin A). White solid, yield 95.2%; melting point 226.9-228.1°C. 1 HNMR(600MHz, CDCl3)δ6.25(s,1H),5.43(d,J=5.2Hz,1H),5.28-5.30(m,1H),4.14(dd,J=8.6,7.0Hz,1H),3 .85(t,J=9.2Hz,1H),3.68-3.62(m,1H),3.42(d,J=7.8Hz,1H),3.32-3.29(m,1H),2.60-2.53(m,1H),2.48-2 .37(m,2H),2.34(dd,J=13.6,5.3Hz,1H),2.27-2.20(m,1H),2.16(dd,J=12.8,4.6Hz,1H),2.06-2.03(m,2H) ,1.52(s,3H),1.37-1.31(m,1H),1.28-1.25(m,1H),1.25-1.22(m,1H),1.04(t,J=12.2Hz,1H),0.95(s,3H). 13 C NMR (150MHz, CDCl3) δ175.4,143.5,138.9,121.1,118.3,113.9,76.2,75.2, 72.3,67.6,55.8,52.6,44.2,40.1,39.9,38.9,29.7,28.0,24.6,23.6,19.2. HRMS(ESI)calcd for C 21 H 28 O6Na[M+Na] + ,399.1784;found,399.1781; (c 0.92, MeOH).

[0051] Example 3 Synthesis of glaucogenin C derivatives 5e, 5g, 5h, 5j, 5k and 5l

[0052]

[0053] Synthesis of derivative 5e Compound 3 (36.0 mg, 0.1 mmol) was weighed and dissolved in 5 mL of dichloromethane, and 15.31 μL (0.15 mmol) of acetic anhydride, 1 mL of pyridine, and 1.22 mg (0.01 mmol) of 4-dimethylaminopyridine were added to the solution at 0 ° C under nitrogen protection and mixed and stirred for reaction. The mixture was warmed to room temperature and stirred for 2-12 hours. Next, 40 mL of saturated NaHCO3 solution was added to the solution, and the resulting mixture was extracted three times with 40 mL of ethyl acetate. Then, the organic layer was washed with saturated brine, dried with Na2SO4, and concentrated under vacuum. The crude product was purified by flash chromatography to obtain pure compound 5e. White solid, yield 92.3%; melting point 216.7-218.3 ° C. 1 H NMR (600MHz, CDCl3) δ6.25 (s, 1H), 5.43 (d, J = 5.2Hz, 1H), 5.30-5.28 (m, 1H), 4.63-4.56 (m, 1H), 4.16 (dd, J = 8.6, 7. 0Hz,1H),3.85(t,J=9.6Hz,1H),3.44(d,J=7.8Hz,1H),2.57(m,1H),2.48-2.41(m,2H),2.37-2.35(m,1H),2.27-2. 21(m,1H),2.06-2.04(m,2H),2.03(s,3H),1.97(dt,J=13.4,3.4Hz,1H),1.93-1.88(m,1H),1.53(s,3H),1.44-1.4 0(m,1H),1.36-1.34(m,1H),1.33-1.29(m,1H),1.20(t,J=10.2Hz,1H),1.14(td,J=13.8,3.8Hz,1H),0.94(s,3H). 13 C NMR (150MHz, CDCl3) δ175.4,170.4,143.2,139.1,121.1,118.1,113.8,75.0,73.5, 67.5,55.6,52.6,40.3,38.3,37.7,36.1,29.5,27.9,27.4,24.5,23.5,21.3,17.8. HRMS(ESI)calcd for C 23 H 30 O6Na[M+Na] + ,425.1940;found,425.1929; (c 0.16, MeOH).

[0054] Synthesis of derivative 5g Compound 3 (0.1mmol) was weighed and mixed with pyridine (1mL) and dichloromethane (2mL), and the corresponding amount of p-chlorobenzoyl chloride (0.15mmol) was added under nitrogen protection at room temperature and reacted for 24 hours. Water was then added to suspend the mixture, and the mixture was extracted with ethyl acetate. The combined extracts were washed with saturated brine and dried over anhydrous Na2SO4. The organic solution was filtered and concentrated under vacuum. The combined extracts were purified by column chromatography on a silica gel column to obtain the corresponding target compound 5g. White solid, yield 40.8%; melting point 202.9-204.2°C. 1 H NMR(600MHz, CDCl3)δ7.96(dt,J=9.0,2.4Hz,2H),7.40(dt,J=9.2,2.4Hz,2H),6.26(s,1H),5.49(d,J=5.2Hz,1H),5.3 5-5.27(m,1H),4.86-4.83(m,1H),4.17(dd,J=8.6,7.0Hz,1H),3.86(t,J=9.6Hz,1H),3.45(d,J=7.8Hz,1H),2.63-2.5 5(m,1H),2.52-2.48(m,1H),2.47-2.45(m,1H),2.42-2.36(m,1H),2.10-2.02(m,4H),1.79-1.71(m,1H),1.54(s,3H), 1.38-1.36(m,1H),1.33-1.31(m,1H),1.30-1.28(m,1H),1.27-1.25(m,1H),1.21(td,J=14.8,4.6Hz,1H),0.99(s,3H). 13 CNMR (150MHz, CDCl3) δ175.5,165.2,143.4,139.4,139.2,131.1,131.1,129.2,128.8,128.8,121.5,1 18.2,114.1,75.2,74.6,67.7,55.8,52.8,40.5,38.6,37.9,36.3,29.7,28.1,27.7,24.7,23.7,18.1. HRMS(ESI)calcd for C 28 H 31 ClO6Na[M+Na] + ,521.1707;found,521.1694; (c 0.12, MeOH).

[0055] Synthesis of derivative 5h Compound 3 (0.1 mmol) was weighed and mixed with pyridine (1 mL) and dichloromethane (2 mL), and the corresponding amount of cyclopropanecarbonyl chloride (0.15 mmol) was added under nitrogen protection at room temperature and reacted for 24 hours. Then water was added to suspend the mixture, and the mixture was extracted with ethyl acetate. The combined extracts were washed with saturated brine and dried over anhydrous Na2SO4. The organic solution was filtered and concentrated under vacuum. The combined extracts were purified by column chromatography on a silica gel column to obtain the corresponding target compound 5h. White solid, yield 73.6%; melting point 180.6-182.1°C. 1 HNMR (600MHz, CDCl3) δ6.24 (s, 1H), 5.41 (d, J = 6.0Hz, 1H), 5.31-5.29 (m, 1H), 4.65-4.55 (m, 1H), 4.15 (dd, J = 8.6, 7.0Hz, 1H), 3. 88(t,J=8.6Hz,1H),3.43(d,J=7.8Hz,1H),2.60-2.53(m,1H),2.44-2.42(m,2H),2.38-2.35(m,1H),2.28-2.22(m,1H),2.05-2.0 3(m,2H),1.97(dt,J=13.4,3.4Hz,1H),1.92-1.89(m,1H),1.60(d,J=12.6Hz,1H),1.57-1.55(m,1H),1.53(s,3H),1.38-1.34(m, 1H),1.27-1.25(m,1H),1.22(t,J=10.2Hz,1H),1.12(td,J=13.8,3.6Hz,1H),0.98-0.96(m,2H),0.94(s,3H),0.85-0.82(m,2H). 13 C NMR (150MHz, CDCl3) δ175.3,174.2,143.2,139.1,121.0,118.0,113.8,74.9,73.4,67.4 ,55.6,52.5,40.2,38.3,37.7,36.0,31.3,30.1,27.8,24.4,23.4,17.8,13.0,8.3,8.3. HRMS(ESI)calcd for C 25 H 32 O6Na[M+Na] + ,451.2097;found,451.2090; (c 0.10, MeOH).

[0056] Synthesis of derivative 5j Compound 3 (0.1 mmol) was weighed and mixed with pyridine (1 mL) and dichloromethane (2 mL), and the corresponding amount of 2-furoyl chloride (0.15 mmol) was added under nitrogen protection at room temperature and reacted for 24 hours. Then water was added to suspend the mixture, and the mixture was extracted with ethyl acetate. The combined extracts were washed with saturated brine and dried over anhydrous Na2SO4. The organic solution was filtered and concentrated under vacuum. The combined extracts were purified by column chromatography on a silica gel column to obtain the corresponding target compound 5j. White solid, yield 68.3%; melting point 194.2-195.2°C. 1 HNMR (600MHz, CDCl3) δ7.57(dd,J=3.2,0.8Hz,1H),7.17(d,J=3.6Hz,1H),6.50(q,J=1.8Hz,1H),6.25(s,1H),5.46( d,J=5.2Hz,1H),5.31-5.28(m,1H),4.89-4.80(m,1H),4.16(dd,J=8.6,7.0Hz,1H),3.85(t,J=9.6Hz,1H),3.44(d,J= 7.8Hz,1H),2.62-2.55(m,1H),2.47-2.45(m,2H),2.42-2.37(m,1H),2.05-2.03(m,4H),1.76-1.74(m,1H),1.54(s, 3H),1.39-1.33(m,1H),1.29(dt,J=16.2,3.4Hz,,1H),1.27-1.23(m,2H),1.19(td,J=14.0,4.0Hz,1H),0.98(s,3H). 13 C NMR (150MHz, CDCl3) δ175.4,158.1,146.2,144.9,143.3,139.0,121.4,118.1,117.8,113.9,1 11.8,75.1,74.3,67.5,55.7,52.7,40.3,38.4,37.8,36.1,29.6,28.0,27.6,24.5,23.5,17.9. HRMS(ESI)calcd for C 26 H 30 O7Na[M+Na] + ,477.1889;found,477.1887; (c 0.19, MeOH).

[0057] Synthesis of derivative 5k Compound 3 (0.1 mmol) was weighed and mixed with pyridine (1 mL) and dichloromethane (2 mL), and the corresponding amount of 2-thiophenecarbonyl chloride (0.15 mmol) was added under nitrogen protection at room temperature and reacted for 24 hours. Then water was added to suspend the mixture, and the mixture was extracted with ethyl acetate. The combined extracts were washed with saturated brine and dried over anhydrous Na2SO4. The organic solution was filtered and concentrated under vacuum. The combined extracts were purified by column chromatography on a silica gel column to obtain the corresponding target compound 5k. White solid, yield 64.9%; melting point 191.6-192.8°C. 1 HNMR(600MHz, CDCl3) δ7.79(dd,J=3.8,1.2Hz,1H),7.54(dd,J=5.0,1.2Hz,1H),7.09(dd,J=4.8,3.8Hz,1H),6.26(s,1H),5 .46(d,J=5.2Hz,1H),5.32-5.29(m,1H),4.86-4.77(m,1H),4.16(dd,J=8.6,7.0Hz,1H),3.86(t,J=9.6Hz,1H),3.45(d,J=7 .8Hz,1H),2.62-2.55(m,1H),2.51-2.48(m,1H),2.45(d,J=7.0Hz,1H),2.41-2.35(m,1H),2.10-2.01(m,4H),1.78-1.70(m ,1H),1.54(s,3H),1.40-1.34(m,1H),1.29-1.27(m,1H),1.25(t,J=10.2Hz,2H),1.19(td,J=14.8,4.6Hz,1H),0.99(s,3H). 13 C NMR (150MHz, CDCl3) δ175.3,161.6,143.2,139.0,134.2,133.2,132.1,127.6,121.2,118.0,1 13.8,75.0,74.4,67.4,55.6,52.6,40.3,38.3,37.7,36.0,29.5,27.9,27.5,24.4,23.4,17.9. HRMS(ESI)calcd for C 26 H 30 SO6Na[M+Na] + ,493.1661;found,493.1661; (c 0.18, MeOH).

[0058] Synthesis of derivative 5l Compound 3 (0.1 mmol) was weighed and mixed with pyridine (1 mL) and dichloromethane (2 mL), and the corresponding amount of 4-trifluoromethylthiobenzoyl chloride (0.15 mmol) was added under nitrogen protection at room temperature and reacted for 24 hours. Then water was added to suspend the mixture, and the mixture was extracted with ethyl acetate. The combined extracts were washed with saturated brine and dried over anhydrous Na2SO4. The organic solution was filtered and concentrated under vacuum. The combined extracts were purified by column chromatography on a silica gel column to obtain the corresponding target compound 5l. White solid, yield 85.1%; melting point 199.9-202.1°C. 1 HNMR (600MHz, CDCl3) δ8.07(d,J=8.6Hz,2H),7.71(d,J=8.2Hz,2H),6.26(s,1H),5.48(d,J=5.2Hz,1H),5.32 -5.29(m,1H),4.90-4.83(m,1H),4.17(dd,J=8.6,7.0Hz,1H),3.85(t,J=9.6Hz,1H),3.45(d,J=7.8Hz,1H),2. 63-2.56(m,1H),2.52-2.49(m,1H),2.47-2.45(m,1H),2.42-2.40(m,1H),2.07-2.05(m,4H),1.80-1.72(m,1H ),1.54(s,3H),1.40-1.35(m,1H),1.34-1.28(m,2H),1.26(d,J=10.2Hz,1H),1.21-1.19(m,1H),1.00(s,3H). 13 C NMR (150MHz, CDCl3) δ175.2,164.6,143.1,138.7,135.3,135.3,132.4,130.1,130.1,129.5,128.1,121. 3,117.9,113.6,74.8,74.5,67.3,55.5,52.4,40.1,38.2,37.5,35.9,29.3,27.7,27.3,24.3,23.3,17.7. HRMS(ESI)calcd for C 29 H 31 F3O6SNa[M+Na] + ,587.1691;found,587.1666; (c 0.10, MeOH).

[0059] Example 4 Synthesis of glaucogenin A derivative 10a

[0060]

[0061] Synthesis of derivative 10a. Weigh compound 4 (0.1 mmol) and mix with pyridine (1 mL) and dichloromethane (2 mL), add the corresponding amount of 2-furoyl chloride (0.30 mmol) under nitrogen protection at room temperature, and react for 24 hours. Then add water to suspend, and extract the reaction mixture with ethyl acetate. The combined organic layer is washed with saturated brine, dried with Na2SO4, and concentrated under vacuum. The extract is purified by flash chromatography to obtain pure compound 10a. White solid, yield 35.5%; melting point 200.9-202.3°C. 1 HNMR (600MHz, CDCl3) δ7.53(s,2H),7.11(dd,J=9.6,3.6Hz,2H),6.45(td,J=3.6,1.6Hz,2H),6.25(s,1H),5.57(d ,J=5.2Hz,1H),5.48-5.46(m,1H),5.32-5.31(m,1H),5.13-5.07(m,1H),4.16(dd,J=8.6,7.0Hz,1H),3.85(t,J=9. 2Hz,1H),3.43(d,J=8.2Hz,1H),2.66(dd,J=13.6,5.8Hz,1H),2.61-2.55(m,1H),2.52-2.50(m,1H),2.45-2.43(m, 2H),2.12-2.10(m,2H),2.06-2.04(m,1H),1.53(s,3H),1.30(d,J=4.6Hz,2H),1.28(d,J=5.6Hz,2H),1.12(s,3H). 13 C NMR (150MHz, CDCl3) δ174.8,157.8,157.7,146.3,146.3,143.9,143.2,143.2,136.6,122.4,118.1,118.1,117. 9,113.3,111.6,111.6,74.9,74.4,71.5,67.2,55.4,52.0,41.2,39.6,39.5,31.2,29.9,27.7,24.3,23.2,18.5. HRMS(ESI)calcd for C 31 H 32 O 10 Na[M+Na] + ,587.1893;found,587.1890; (c 0.15, MeOH).

[0062] Example 5 Anti-tobacco mosaic virus activity test results of the synthesized derivatives 5e, 5g, 5h, 5j, 5k, 5l and 10a

[0063] Experimental Methods for Anti-TNV Activity in Plants

[0064] The experiment of compound passivation on TMV: Select healthy and consistent heartleaf tobacco at the 5-6 leaf stage and place it in a dark room overnight. Mix the test compound with 50μg / mL TMV at a ratio of 1:1 (v / v) to the required concentration, mix well and place for 0.5h. Select 4-6 leaves of similar size from each tobacco plant, and rub half of each leaf with 100μL of the mixed solution of compound and TMV as treatment; the other half is rubbed with 100μL of 50μg / mL TMV as positive control; the leaves rubbed with DMSO solution of corresponding concentration are used as blanks. After 2h, wash the diamond dust on the leaf surface with sterile water. Put it in an insect-free greenhouse, and calculate the TMV inhibition rate after 3-4 days according to the formula: [1-(average number of necrotic spots of treatment / average number of necrotic spots of positive control)]×100. Repeat three times for each compound.

[0065] Experiment on the protective effect of compounds on TMV: Select healthy and uniformly growing heartleaf tobacco at the 5-6 leaf stage and place them in a dark room overnight. Select 4-6 leaves of similar size from each tobacco plant, dilute the test compound with sterile water to the required concentration, and evenly apply 100μL of the drug to half of each leaf as treatment. After 24 hours, each leaf is rubbed and inoculated with 200μL of 50μg / mL TMV. The untreated half is used as a positive control, and the leaves that are not rubbed and inoculated with DMSO solution of corresponding concentration are used as blanks. After 2 hours, wash the diamond dust on the leaf surface with sterile water. Put it in an insect-free greenhouse, and calculate the TMV inhibition rate after 3-4 days according to the formula: 1-(average number of necrosis spots of treatment / average number of necrosis spots of positive control)×100. Each compound is repeated three times.

[0066] Compounds for the treatment of TMV: Select healthy and uniformly growing heartleaf tobacco leaves at the 5-6 leaf stage and place them in a dark room overnight. Select 4-6 leaves of similar size from each tobacco plant and rub inoculate 200μL of 50μg / mL TMV. After 2 hours, half of each leaf is evenly sprayed with 100μL of the drug as treatment; the other half is used as a positive control; leaves that are not sprayed and rub inoculated with a corresponding concentration of DMSO solution are used as blanks. After 2 hours, wash the diamond dust on the leaf surface with sterile water. Place in an insect-free greenhouse and calculate the TMV inhibition rate after 3-4 days according to the formula: [1-(average number of necrosis spots for treatment / average number of necrosis spots for positive control)]×100. Repeat three times for each compound.

[0067] Table 1 In vivo anti-TMV activity of compounds (1–4, 5e, 5g, 5h, 5j, 5k, 5l, 10a)

[0068]

[0069] a The half-leaf spot assay was used to evaluate the in vivo passivation effect at a concentration of 50 μg / mL of the test compound. b The half-leaf spot assay was used to evaluate the in vivo protective and therapeutic effects at a concentration of 200 μg / mL of the test compound. c The EC values ​​of the test compound obtained by the passivation effect 50 All results are expressed as mean ± SD; n = 3 for all groups.

[0070] It can be seen from Table 1 that compounds 1-4, 5e, 5g, 5h, 5j, 5k, 5l and 10a all showed strong anti-TMV passivation activity, which was 58.2% higher than the positive control Ningnanmycin. The EC 50 The values ​​were higher than those of the positive control Ningnanmycin. Compounds 5g, 5j and 5l showed better purification, protection and treatment effects than the positive control Ningnanmycin and lead compounds 3 and 4, and are the preferred anti-plant virus candidates. The experimental results of the half-leaf spot method of living tobacco leaves of compounds 5g, 5j and 5l are shown in the photo. Figure 1 As shown by Figure 1 It can also be seen that 5g, 5j and 5l exhibited strong anti-tobacco mosaic virus activity.

[0071] Example 6 Study on the mechanism of the anti-tobacco mosaic virus activity of compounds 5e, 5g, 5h, 5j, 5k, 5l and 10a

[0072] On the third day after the virus-inoculated leaves were treated with compounds 5e, 5g, 5h, 5j, 5k, 5l and 10a, the expression of TMV-CP was detected by Western blotting, and the expression of TMV-CP gene in systemically infected leaves was analyzed by RT-PCR; the expression of Hsp70 was detected by Western blotting; and the expression of NtHSP70-1, NtHSP70-061 and NtHSP70-261 genes in systemically infected leaves were evaluated by RT-qPCR analysis.

[0073] Western blot analysis, the specific steps are as follows:

[0074] Protein extraction: A plant total protein extraction kit was used to extract protein from common tobacco K326 with different treatments.

[0075] Determination of protein concentration: We used the BCA protein quantification kit to measure the protein extract, and the extracted protein was used for subsequent testing.

[0076] Pre-sampling treatment: According to the protein concentration, each sample was loaded at 20 μg. First, anhydrous mercaptoethanol, a protein denaturant, was added and denatured at 95°C for 6 minutes. After the denaturation, it was placed on ice for 5 minutes.

[0077] Loading and electrophoresis: Add the denatured protein sample to the corresponding gel well and start electrophoresis.

[0078] Transfer treatment: Prepare the amount of transfer solution according to the ratio of reagents required for 1L transfer solution (10× transfer solution: anhydrous methanol: water = 1:2:7), and immerse the sponge and filter paper in the transfer solution. Pre-immerse the PVDF membrane in anhydrous methanol for 1 minute to activate it. Make a transfer plate in the order of sponge-filter paper-gel-membrane-filter paper-sponge (protein is negatively charged and will be transferred to the positive electrode and transferred to the PVDF membrane), put the transfer plate into the transfer device, add the transfer solution and start the transfer. The transfer process needs to be carried out under ice bath conditions.

[0079] Blocking treatment: Place the PVDF membrane with transferred protein in TBST containing 5 wt% skim milk and shake it slowly on a shaker for 2 h.

[0080] Primary antibody incubation: After blocking, rinse the PVDF membrane gently with TBST to remove the residual skim milk on the PVDF membrane. Cut the PVDF according to the molecular weight of the target protein, add the corresponding antibody, and incubate it on a shaker at 4°C overnight.

[0081] Secondary antibody incubation: On the second day, recover the primary antibody and rinse the PVDF membrane with TBST for 5 min / time for 3 times to ensure that the residual primary antibody on the PVDF membrane is washed away. Then, label the corresponding secondary antibody according to the species of the primary antibody (the secondary antibody is prepared with 5wt% skim milk). Incubate on a shaker at room temperature for 1 hour.

[0082] Washing the secondary antibody: discard the secondary antibody and rinse the PVDF membrane with TBST, 5 min / time, 3 times to ensure that the residual secondary antibody on the PVDF membrane is completely washed away.

[0083] Development: Use Bio-Rad fluorescent image analyzer to develop and obtain the desired protein target band.

[0084] RNA extraction

[0085] Total RNA was extracted using the RNAeasy kit. The A260 / A280 ratio of total RNA was measured on a NanoDrop biophotometer, and only samples with a ratio between 1.8 and 2.0 were used in subsequent experiments. The quality and integrity of the RNA samples were also assessed based on the 28S and 18S rRNA bands on a 1wt% agarose gel. Approximately 1.5 μg of total RNA from each sample was used to prepare RNA-seq libraries.

[0086] Total RNA was extracted, reverse transcribed, and real-time quantitative PCR (RT-qPCR) was used to detect the expression of corresponding genes.

[0087] RNA was extracted according to the total RNA extraction kit and experimental method. The concentration of the extracted total RNA was measured using a NanoDrop 2000 ultra-micro spectrophotometer, and then about 1.5 μg of total RNA was taken and cDNA was synthesized using M-MLV reverse transcriptase. The specific system is shown in Tables 2-3:

[0088] Table 2A Liquid

[0089]

[0090] Table 3B Liquid

[0091]

[0092] Place the prepared solution A on a PCR machine at 70°C for 5 minutes, then quickly transfer to ice for 5 minutes. Add solution B to solution A and place on a PCR machine at 37°C for 1 hour to obtain cDNA.

[0093] Using the cDNA prepared as above as a template and the corresponding gene-specific quantitative primers (Table 4), a quantitative PCR reaction was performed. The specific reaction system is shown in Table 5.

[0094] Table 4 Primer information

[0095]

[0096] Table 5 Reaction system

[0097] Upstream primer (10 μM) 0.5μL Downstream primer (10 μM) 0.5μL cDNA 1μL SYBR reagent 10μL <![CDATA[ddH2O]]> 8μL

[0098] The reaction procedure was: 95°C, 5 min, 95°C, 10 s, 58°C, 30 s, 40 cycles. After the reaction was completed, the PCR product was taken to draw a standard curve, and the expression level of the relevant gene was further calculated by the standard curve. The experimental results are shown in Figure 2-Figure 4 shown.

[0099] Figure 2Analysis of TMV-CP protein and gene expression. A. The expression of TMV-CP was detected by Western blotting on the 3rd day after the virus-infected leaves were treated with compounds 5e, 5g, 5h, 5j, 5k, 5l and 10a. B. RT-PCR analysis of the expression of TMV-CP gene in systemically infected leaves; Figure 2 It can be seen that these compounds reduce the expression of tobacco mosaic virus coat protein (TMV-CP) and the replication of the TMV-CP gene.

[0100] Figure 3 On the third day after the virus-inoculated leaves were treated with compounds 5e, 5g, 5h, 5j, 5k, 5l and 10a, the expression of Hsp70 was detected by Western blotting. The results showed that these compounds had little effect on the heat shock protein Hsp70.

[0101] Figure 4 The expression of NtHSP70-1, NtHSP70-061, and NtHSP70-261 genes in systemically infected leaves was evaluated by RT-qPCR analysis 3 days after treatment of virus-inoculated leaves with compounds 5e, 5g, 5h, 5j, 5k, 5l, and 10a, and these derivatives downregulated the expression of NtHSP70-1 and tHSP70-061.

[0102] In summary, the present invention provides a novel structure of an anti-TOBMV derivative, and its anti-TOBMV activity is related to reducing the expression of TOBMV coat protein (TMV-CP) and the replication of TMV-CP gene. 21 The inhibition of tobacco mosaic virus infection by steroidal derivatives was also associated with a reduction in the levels of NtHsp70-1 and NtHsp70-061.

[0103] The above description is only a preferred specific implementation manner of the present invention, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can make equivalent replacements or changes according to the technical scheme and inventive concept of the present invention within the technical scope disclosed by the present invention, which should be covered by the protection scope of the present invention.

Claims

1. Bifidobacterium type C 21 A steroidal derivative, characterized in that The structure of the derivative is shown in general formula I or general formula II: In the general formulae I and II, R1, R2, and R3 are selected from the group consisting of hydrogen, alkanes, alkenes, dienes, alkynes, benzene, biphenyl, condensed aromatic rings, aromatic heterocycles, various electron-donating and electron-withdrawing aromatic rings, carboxyl groups, ester groups, acyl groups, and cyano groups.

2. The bisected pregnane type C according to claim 1. 21 A steroidal derivative, characterized in that The derivative is compound 5e, 5g, 5h, 5j, 5k, 5l or 10a; The structural formula of the compound 5e, 5g, 5h, 5j, 5k, 5l or 10a is as follows:

3. A bisected pregnane type C according to claim 2 21 A method for preparing a steroid derivative, characterized in that: The synthesis method of the compound 5e, 5g, 5h, 5j, 5k or 5l is as follows: Step (1) Biscission Pregnane Type C 21 The steroid compound 1 is dissolved in tetrahydrofuran, and HCl solution is added thereto, and the mixture is heated and stirred for reaction; after the reaction is completed, the mixture is cooled to room temperature, an alkali solution is added to the reaction system for neutralization, and then extracted with dichloromethane; after concentration, the crude product is purified by flash chromatography to obtain compound 3; The structural formulas of the compounds 1 and 3 are as follows: Step (2) The 3-hydroxyl group in compound 3 undergoes nucleophilic substitution reaction with the corresponding acyl chloride compound to obtain compound 5e, 5g, 5h, 5j, 5k or 5l.

4. The bisected pregnane type C according to claim 2 21 A method for preparing a steroid derivative, characterized in that: The synthesis method of compound 10a comprises the following steps: Step S1: Biscispregnane type C 21 The steroid compound 2 is dissolved in tetrahydrofuran, and HCl solution is added thereto, and the obtained mixture is heated and stirred for reaction; the mixture is then cooled to room temperature, and an alkali solution is added for neutralization; the obtained mixture is extracted with dichloromethane, and the extract is concentrated under vacuum; the crude product is purified by flash chromatography to obtain compound 4; The structural formulas of the compounds 2 and 4 are as follows: Step S2: Weigh compound 4, pyridine and dichloromethane, add a corresponding amount of 2-furoyl chloride to react under nitrogen protection at room temperature; then suspend in water, and extract the reaction mixture with ethyl acetate; wash the combined organic layer with saturated brine, dry with Na2SO4, and concentrate under vacuum; purify the extract by flash chromatography to obtain pure compound 10a.

5. The bisected pregnane type C according to claim 1 or 2. 21 Application of steroidal derivatives in inhibiting, preventing, controlling or treating tobacco mosaic virus.

6. The bisected pregnane type C according to claim 5. 21 The use of steroidal derivatives in inhibiting, controlling or treating tobacco mosaic virus is characterized in that: Compound 5g, 5j, 51 or a pharmaceutically acceptable salt, ester or stereoisomer thereof can be used alone as an anti-tobacco mosaic virus preparation.

7. The bisected pregnane type C according to claim 6. 21 The use of steroidal derivatives in inhibiting, controlling or treating tobacco mosaic virus is characterized in that: The derivative can be used in combination with other carriers, other antiviral preparations or pesticides, and the percentage content of the derivative is 0.1% to 99.9%.

Citation Information

Patent Citations

  • Application of C21 steroid compounds 1-8 of cynanchum paniculatum in preparation of anti-TSWV active products

    CN111418595A